Repare Therapeutics

Repare has announced updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at #ENA2024. This analysis demonstrates a successful approach to mitigating mechanism-based anemia while maintaining clinical benefit in patients with advanced, genetically-selected solid tumors. We look forward to sharing efficacy data from the gynecological cancer expansion cohort of MYTHIC in December 2024. Learn more here: https://lnkd.in/gn-5FdEJ

Inviting all attendees of the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics at the CCIB in Barcelona to join Dr. Martin Højgaard and Repare Therapeutics for a presentation on the impact of individualised schedule optimisation in our Phase 1 MYTHIC Study with lunresertib and camonsertib. See you at #ENA2024!

Join Repare's Director of Bioinformatics, Ian Silverman, at the 36th EORTC - European Organisation for Research and Treatment of Cancer - National Cancer Institute (NCI) - AACR Journals Symposium on Molecular Targets and Cancer Therapeutics next week when he will speak about the importance of #bioinformatics to patient trial matching. #precisiononcology

We are one step closer to potentially improving the lives of patients with the first patient dosed with RP-3467, our potential best-in-class Polθ ATPase inhibitor. RP-3467 has demonstrated highly compelling preclinical results, including complete and durable tumor regressions in combination with olaparib with no additive toxicities. This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, an area of high unmet medical need. Learn more here: https://lnkd.in/ebSbQbAy #precisiononcology

Thank you to investigators at Memorial Sloan Kettering Cancer Center for presenting the results of our collaboration at American Society for Radiation Oncology (ASTRO)'s annual meeting highlighting encouraging responses for camonsertib in combination with #radiotherapy treatment. Learn more here: https://lnkd.in/ePapuJWZ #ASTRO24 #precisionmedicine #syntheticlethality

We presented new data at AACR Journals' 15th Annual Ovarian Cancer Research Symposium in Seattle highlighting the impact and inherent chemotherapy resistance of alterations in CCNE1, FBXW7, and PPP2R1A in patients with metastatic ovarian and endometrial cancers based on an analysis in ~2,000 patients from Cancer Genome Atlas Research Network and Memorial Sloan Kettering Cancer Center's Metastatic Events and Tropisms. Given the lack of treatment options for metastatic gynecologic cancer patients with these biomarkers, we look forward to reporting data from our MYTHIC dose expansion trial in Q4 2024. https://lnkd.in/eB9NfkiW #precisiononcology

Join us Saturday September at ESMO - European Society for Medical Oncology where we will share new data from Module 1 of our ongoing Phase 1/2 TRESR clinical trial. Learn more here: https://lnkd.in/eziPnteJ #precisiononcology #syntheticlethality #clinicaltrials

Join Repare Therapeutics at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference this week for a company presentation. Click here to join the webcast: https://lnkd.in/ei4nApun $RPTX

Tune in with Repare Therapeutics’s management team in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference in NYC today. We look forward to connecting in person! Click here to watch the webcast: https://lnkd.in/eYYbV943

Join us next Wednesday at American Chemical Society's #ACSFall2024 as Repare Therapeutics presents, "RP-3467: potent, selective Polθ inhibitor against BRCA-mutated tumors and other HR-deficient genetic backgrounds." We expect this potential best-in-class Polθ ATPase inhibitor program to enter the clinic in the fourth quarter of this year! #precisionmedicine #syntheticlethality